TICKERNERD
Menu
PPCBPPCBHealthcare · Biotechnology

PPCB Stock Forecast: Propanc Biopharma, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$0.61

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 19 Sept 2026 — in the lower half.

Market cap
$1.4M
Ticker Nerd rank
40 / 100
Median analyst target
—
Analysts covering
0
Revenue$0.0
Operating income−$6.4M
Net income−$6.4M
Free cash flow−$1.1M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Ticker Nerd rank

PPCB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Propanc Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
99
Accruals
97
Growth
69
Quality
65
Volatility
33
Revisions
25
Momentum
21
Value
17
Issuance
11

Size (99): Smaller than most of the companies we track.

Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PPCB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PPCB, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PPCB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PPCB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Propanc Biopharma, Inc. (PPCB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
—
Price / book
0.1×

Cheaper than 91% of US stocks

EV / EBITDA
−0.1×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−127.0%

Higher than 11% of US stocks

Return on assets
−62.3%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Propanc Biopharma, Inc. (PPCB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Propanc Biopharma, Inc. has a market value of $1.4M and an enterprise value of $2.5M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$18.4M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$4.1M.

  • Shares outstanding: 874,371.

  • Trailing P/E: 0.0×.

  • Propanc Biopharma, Inc. employs 1 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

PPCB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PPCBPropanc Biopharma, Inc.$1.4M
40
ARTLArtelo Biosciences, Inc.$2.2M
15
CRISCuris, Inc.$2.1M
36
OGENOragenics, Inc.$2.1M
10
MTNBMatinas BioPharma Holdings, Inc.$2.4M
44
CDTCDT Equity, Inc.$2.4M
11
SLXNSilexion Therapeutics Corp.$2.4M
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Propanc Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PPCB news & analysis

Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.

GlobeNewsWire · 16 Sept 2026positive

Propanc Biopharma issued a comparative analysis positioning its lead candidate PRP's EMT-reversal mechanism as a potential complementary backbone therapy alongside emerging RAS inhibitors from Revolution Medicines, Inc. and Erasca, Inc., referencing clinical data from their respective RAS-targeted programs.

Why it matters — This strategic positioning suggests Propanc is highlighting a potential differentiated and synergistic role for PRP in the growing RAS-targeted oncology landscape, which could expand its therapeutic relevance.

Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027

GlobeNewsWire · 9 Sept 2026positive

Propanc Biopharma announced plans to commence a world-first Phase 1b first-in-human study of PRP, its investigational treatment, in February 2027. The company develops novel treatments for chronic diseases, including recurrent and metastatic cancer.

Why it matters — This marks significant clinical progress for PPCB as it advances PRP toward its first-in-human study, a key milestone for the company's development pipeline.

Revolution Medicines' Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma's Breakthrough Survival Results

Benzinga · 27 Aug 2026positive

Propanc Biopharma (NASDAQ:PPCB) stock surged on Thursday following compelling preclinical and early translational data for its lead drug candidate, PRP, which is being developed to treat pancreatic ductal adenocarcinoma. The rise was also supported by an approval in pancreatic cancer treatment in the broader sector.

Why it matters — The release of promising preclinical and early translational data for PRP signals potential progress for Propanc Biopharma's lead pancreatic cancer candidate.

Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit

GlobeNewsWire · 27 Aug 2026positive

Propanc Biopharma announced new preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC). In orthotopic and patient-derived xenograft models of advanced PDAC, three-times-weekly intravenous PRP achieved greater than 90% mean tumor growth inhibition versus vehicle controls (p < 0.001).

Why it matters — This positive preclinical efficacy data for PRP in pancreatic cancer could be relevant to a PPCB watcher as it represents a potential development milestone for the company's lead candidate.

Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP

GlobeNewsWire · 18 Aug 2026positive

Propanc Biopharma announced it has begun finalizing a clinical trial protocol and will conduct a feasibility assessment for its First-In-Human Phase 1b clinical study of PRP in up to 40 advanced cancer patients with solid tumors. Preparatory activities, led by Avance Clinical Pty Ltd, include reviewing the Investigator's Brochure, preparing a Briefing Document, and finalizing the Clinical Trial Protocol.

Why it matters — This marks a step toward the company's first-in-human clinical study of its PRP cancer therapy, a key milestone for PPCB's development pipeline.

FAQ

Frequently asked questions about PPCB stock

How does Ticker Nerd's model rank PPCB?

As at 19 Sept 2026, Propanc Biopharma, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

What is the PPCB stock forecast for 2030?

No analyst covering Propanc Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PPCB are extrapolating price history, which says nothing about the business.

What does Propanc Biopharma, Inc. do?

Propanc Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments for patients with pancreatic, ovarian, and colorectal cancers.

What is the latest news on PPCB?

The most recent item we track (GlobeNewsWire, 16 Sept 2026): "Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.". Propanc Biopharma issued a comparative analysis positioning its lead candidate PRP's EMT-reversal mechanism as a potential complementary backbone therapy alongside emerging RAS inhibitors from Revolution Medicines, Inc. and Erasca, Inc., referencing clinical data from their respective RAS-targeted programs.

Company

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments for patients with pancreatic, ovarian, and colorectal cancers. The company’s current work centers on proenzyme-based therapies designed to address recurring and metastatic disease, with an emphasis on helping control tumor spread and reduce recurrence. Its product pipeline includes lead candidates such as PRP and POP1, which are being developed as long-term therapeutic options for solid tumors. Propanc Biopharma operates in the oncology-focused biotechnology segment of the life sciences market, where it contributes to the development of novel approaches for chronic and advanced cancer care. Headquartered in Camberwell, Australia, the company is positioned as a specialized developer of experimental cancer therapies for use in clinical and preclinical settings.

CEO Mr. James Nathanielsz · 1 employees · Australia · https://www.propanc.com